Cardiovascular and metabolic disease in the liver transplant recipient

Area of Science:

• Hepatology
• Cardiology
• Transplantation Medicine

Background:

• Liver transplantation significantly improves survival for decompensated liver disease and liver cancer.
• Cardiovascular disease is a primary cause of death in liver transplant recipients, linked to metabolic risk factors.
• Metabolic syndrome, characterized by obesity, hypertension, dyslipidemia, and diabetes, is increasingly prevalent post-transplant.

Purpose of the Study:

• To review the incidence and contributing factors of post-transplant metabolic disease.
• To examine the burden of cardiovascular disease in liver allograft recipients.
• To identify high-risk patient groups and management strategies.

Main Methods:

• Literature review of studies on liver transplantation outcomes.
• Analysis of post-transplant metabolic risk factors and cardiovascular disease prevalence.
• Discussion of patient demographics and disease indications for transplantation.

Main Results:

• Post-transplant metabolic syndrome is rising due to aging recipients, increased general population risk factors, non-alcoholic steatohepatitis, and longer survival.
• Patients with pre-transplant diabetes or obesity are at higher risk for post-transplant metabolic syndrome.
• Aggressive management of metabolic risk factors and potential immunosuppression adjustment are key.

Conclusions:

• Post-transplant metabolic syndrome poses a growing threat to liver allograft recipient morbidity and mortality.
• Close surveillance and proactive medical management of metabolic factors are essential, especially for high-risk patients.
• Immunosuppressive regimen adjustments may mitigate cardiovascular risk but require careful consideration to prevent graft failure.